Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more) Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more) Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Actinium Pharmaceuticals Inc ATNM

Healthcare Biotechnology
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A... see more

Recent & Breaking News (NYSEAM:ATNM)

Actinium Files Orphan Drug Application for Use of Iomab-B in Treating Refractory and Relapsed Acute Myeloid Leukemia in Elderly Patients

Marketwired November 23, 2015

Actinium Submits Iomab-B IND Application to the U.S. FDA

Marketwired November 17, 2015

Actinium Pharmaceuticals Further Strengthens Product Development Efforts With Senior Level Hires

Marketwired November 4, 2015

Actinium Announces Data From Actimab-A Trial has Been Accepted for Poster Presentation at American Society of Hematology Annual Meeting

Marketwired October 26, 2015

Actinium Announces Completion of the Fourth and Final Cohort of Its Actimab-A Trial

Marketwired October 15, 2015

Actinium Pharmaceuticals Further Strengthens Team Adding an Accomplished Finance and Corporate Development Professional

Marketwired October 13, 2015

Actinium Targets Fourth Quarter IND Filing for Iomab-B Subsequent to Pre-IND Meeting With FDA

Marketwired October 6, 2015

Actinium to Participate at the FBR Second Annual Healthcare Conference

Marketwired September 9, 2015

Actinium to Present at Rodman & Renshaw 17th Annual Global Investment Conference

Marketwired September 2, 2015

Key Executive With Significant Hematology Drug Development Expertise Joins Actinium Pharmaceuticals as Head of Clinical Development

Marketwired August 18, 2015

Actinium Successfully Labels Antibody with Actinium-225 For Next Entry into Pipeline

Marketwired August 10, 2015

Global Markets Crashing, 4 Small Cap Stocks To Watch

Accesswire August 6, 2015

Global Markets Crashing, 4 Small Cap Stocks To Watch

Accesswire August 6, 2015

Actinium Issues Letter to Shareholders Outlining Measures to Move Iomab-B and Actimab-A Into Advanced Development

Marketwired August 5, 2015

Actinium Advances Iomab-B Towards Phase 3 With Pre-IND Meeting Request

Marketwired July 15, 2015

Actinium Files a Provisional Patent Application for Infusion Administration of Iomab-B

Marketwired June 24, 2015

Actinium Announces Closing of $5 Million Registered Direct Offering of Common Stock

Marketwired June 9, 2015

Actinium Announces $5 Million Registered Direct Offering of Common Stock

Marketwired June 4, 2015

Actinium's Clinical Data Generate Significant Interest at 2015 ASCO Annual Meeting

Marketwired June 4, 2015

Actinium's Actimab-A High Response Rates Presented at 2015 ASCO Annual Meeting

Marketwired May 29, 2015